Protective Immunity Transferred by Infusion of Cytomegalovirus-Specific CD8+ T Cells within Donor Grafts: Its Associations with Cytomegalovirus Reactivation Following Unmanipulated Allogeneic Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 7, 2010, Pages 994-1004

  Luo, Xiao Hua ^a   Huang, Xiao Jun ^b   Liu, Kai Yan ^b   Xu, Lan Ping ^b   Liu, Dai Hong ^b  

^a CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Antigen specific CTL; CMV reactivation; Donor grafts

Indexed keywords

DACLIZUMAB; METHOTREXATE; METHYLPREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOPHENOTYPING; INCIDENCE; LYMPHOCYTE COUNT; MALE; MONONUCLEAR CELL; MYELOABLATIVE CONDITIONING; PERIPHERAL BLOOD STEM CELL; PHENOTYPE; VIRUS REACTIVATION;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPITOPES, T-LYMPHOCYTE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION;

EID: 77953622637     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.02.007     Document Type: Article

References (58)

1. Nichols W.G., Corey L., Gooley T., et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002, 185:273-282.
2. Boeckh M., Nichols W.G. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004, 103:2003-2008.
3. Reusser P., Einsele H., Lee J., et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002, 99:1159-1164.
4. Goodrich J.M., Mori M., Gleaves C.A., et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991, 325:1601-1607.
5. Boeckh M., Gooley T.A., Bowden R.A. Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia. J Infect Dis 1998, 178:1153-1157.
6. + T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants. Transplantation 2002, 74:722-732.
7. + T cells following allogeneic hemopoietic stem cell transplantation. Blood 2003, 102:3427-3438.
8. + T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001, 98:1358-1364.
9. Cwynarski K., Ainsworth J., Cobbold M., et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001, 97:1232-1240.
10. + T cells. Blood 2002, 100:3690-3697.
11. + T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica 2008, 93:248-256.
12. + T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood 2006, 108:1406-1412.
13. Walter E.A., Greenberg P.D., Gilbert M.J., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995, 333:1038-1044.
14. Cobbold M., Khan N., Pourgheysari B., et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005, 202:379-386.
15. Micklethwaite K.P., Clancy L., Sandher U., et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 2008, 112:3974-3981.
16. Micklethwaite K., Hansen A., Foster A., et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:707-714.
17. + TEMRA cells in early infection are linked to control of HIV-1 viremia and predict the subsequent viral load set point. J Virol 2007, 81:5759-5765.
18. Lanzavecchia A., Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005, 17:326-332.
19. + T cells in protection against CMV disease. Blood 2003, 101:2686-2692.
20. Sallusto F., Lenig D., Forster R., et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
21. + cell subsets after different hematopoietic cell transplant types: possible influence in the recovery of anti-cytomegalovirus immune response and risk for its reactivation. Clin Immunol 2006, 119:261-271.
22. Date Y., Kimura A., Kato H., et al. DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese. Tissue Antigens 1996, 47:93-101.
23. Imanishi, T., T. Akaza, A. Kimura, K. Tokunaga, and T. Gojobori. 1992. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. HLA 1991, Proceedings of the Eleventh International Histocompatibility Workshop and Conference. K. Tjuji, M. Aizawa, and T. Sasazuki, editors. Oxford University Press, Oxford/New York/Tokyo. 1065 -1220.
24. Lu D.-P., Dong L., Wu T., et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006, 107:3065-3073.
25. Huang X.J., Liu D.H., Liu K.Y., et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006, 38:291-297.
26. Huang X.J., Jiang Q., Chen H., et al. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2005, 36:343-348.
27. Huang X.J., Liu D.H., Liu K.Y., et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009, 15:257-265.
28. Luo X.H., Chang Y.J., Xu L.P., et al. The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched//haploidentical hematopoietic SCT. Bone Marrow Transplant 2008, 43:29-36.
29. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094-1097.
30. Zhou W., Longmate J., Lacey S.F., et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood 2009, 113:6465-6476.
31. Khan N., Shariff N., Cobbold M., et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 2002, 169:1984-1992.
32. + T cells expressing the inhibitory killer cell lectin-like receptor G1 (KLRG1). Exp Gerontol 2003, 38:911-920.
33. Khan N., Hislop A., Gudgeon N., et al. Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J Immunol 2004, 173:7481-7489.
34. Einsele H., Kapp M., Grigoleit G.U. CMV-specific T cell therapy. Blood Cells Mol Dis 2008, 40:71-75.
35. + T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential. Blood 2002, 100:933-940.
36. + T cells comprise both naive and memory cells. J Immunol 1999, 162:7080-7087.
37. + T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA 2009, 106:17469-17474.
38. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 2005, 102:9571-9576.
39. + T cells have a distinct cytokine signature characterized by CC chemokine production without IL-2 production. J Immunol 2009, 183:6167-6174.
40. Harari A., Dutoit V., Cellerai C., et al. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev 2006, 211:236-254.
41. Michie C.A., McLean A., Alcock C., et al. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 1992, 360:264-265.
42. - subsets suggest differentiation independent of CD45RA expression. Blood 2007, 109:2863-2870.
43. + T cells. J Immunol 2002, 169:5838-5843.
44. - T cells is associated with decreased Akt (Ser473) phosphorylation. J Immunol 2007, 178:7710-7719.
45. + T cells. J Clin Invest 2007, 117:492-501.
46. The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor. Scheinberg et al. Blood 2009, 114:5071-5080.
47. Franzke A., Piao W., Lauber J., et al. G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. Blood 2003, 102:734-739.
48. Jun H.X., Jun C.Y., Yu Z.X. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 2004, 89:1517-1524.
49. Champagne P., Ogg G.S., King A.S., et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001, 410:106-111.
50. Mackall C.L., Gress R.E. Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol Rev 1997, 157:61-72.
51. Rezvani K., Yong A.S.M., Savani B.N., et al. Graft-versus-leukemia effects associated with detectable Wilms tumor 1-specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007, 110:1924-1932.
52. Chalandon Y., Degermann S., Villard J., et al. Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications. Blood 2006, 107:389-396.
53. Carrasco J., Godelaine D., Van Pel A., et al. CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation. Blood 2006, 108:2897-2905.
54. Szmania S., Galloway A., Bruorton M., et al. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood 2001, 98:505-512.
55. Hobeika A., Osada T., Serra D., et al. Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease. Cytotherapy 2008, 10:289-302.
56. Bunde T., Kirchner A., Hoffmeister B., et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005, 201:1031-1036.
57. + T cells and control of HCMV replication after allogeneic stem cell transplantation. J Virol 2008, 82:10143-10152.
58. Waller E.C., Day E., Sissons J.G., et al. Dynamics of T cell memory in human cytomegalovirus infection. Med Microbiol Immunol 2008, 197:83-96.